Senior Post Doctoral Researcher/Team Leader
The current focus is understanding and improving upon cell penetrating peptide design to enhance the therapeutic potential of antisense oligonucleotides, in particular for neuromuscular disorders. I am also studying the potential benefit of stereopure oligonucleotides in a severe model of DMD (DKO) through collaboration with Wave LifeSciences.
Cell-Penetrating Peptides to Enhance Delivery of Oligonucleotide-Based Therapeutics.
McClorey G. and Banerjee S., (2018), Biomedicines, 6
PROFILE OF CIRCADIANLY REGULATED METABOLIC GENES IN DYSTROPHIC HEART
Betts CA. et al, (2018), HEART, 104, A4 - A4
Peptide-conjugated phosphodiamidate oligomer-mediated exon skipping has benefits for cardiac function in mdx and Cmah-/-mdx mouse models of Duchenne muscular dystrophy.
Blain AM. et al, (2018), PLoS One, 13
Preclinical studies of WVE-210201, an investigational stereopure antisense oligonucleotide in development for the treatment of patients with duchenne muscular dystrophy (DMD)
Panzara M. et al, (2017), JOURNAL OF THE NEUROLOGICAL SCIENCES, 381, 277 - 278
WVE-210201, an investigational stereopure oligonucleotide therapy for Duchenne muscular dystrophy, induces Exon 51 skipping and dystrophin protein restoration
Wood M. et al, (2017), NEUROMUSCULAR DISORDERS, 27, S217 - S217